Sorafenib, a multikinase inhibitor, exerts antineoplastic effects by inhibiting VEGF receptor (VEGFR), platelet‐derived growth factor receptor‐beta (PDGFR‐β), and Raf/MEK/ERK signaling cascades, thereby inhibiting tumor proliferation and angiogenesis [525]. Here, RAF1 is linked to neoplasm.